



**Alzheimer's disease:
the status quo and the emergence of
new hypotheses (and treatments)**

Paola Sacchetti, Ph.D.

Assistant Professor

Director MS Neuroscience

Department of Biology

University of Hartford, CT

psacchett@hartford.edu



(860)768-5926

Today's talk:

- ❑ Generalities about Alzheimer's disease (AD)
- ❑ Pathology
- ❑ Beta amyloid hypothesis
- ❑ New hypotheses
- ❑ We, at UHart


AD is the most prominent form of dementia

Incidence



Alois Alzheimer

(1864-1915)




1906 He reported “A peculiar severe disease process of the cerebral cortex” which affected a woman in her fifties, Auguste D., and caused memory loss, disorientation, hallucinations and ultimately her death (at 55).

1907 His report noted distinctive plaques and neurofibrillary tangles in the brain histology.





Symptoms of disease progression



This is not normal aging

Pathology of the disease - structural changes



Purve 5th ed.

- Smaller size
- Decreased Cortex (atrophy)

- Bigger ventricles
- Loss of Hippocampus & Entorhinal cortex

- Loss of Acetylcholine neurons

Davies P and Maloney, *Lancet* 1976
Bartus et al, *Science* 1982


Pathology of the disease - Microscopic changes



Plaques –
Extracellular deposits
Mostly composed of
Beta amyloid protein
Glenner and Wong, *BBRC* 1984


Tangles of neurofilaments
Intracellular deposits
Mostly composed of
Tau protein
Brion JP et al, 1985
Wood et al, *PNAS* 1986

Distribution of toxic aggregates in AD brains



A SLOW MARCH

By the time that a person begins to experience the symptoms of Alzheimer's disease, the condition is already well-established in the brain. The accumulation of amyloid- β , generally thought to be the first step in disease progression, could precede symptoms by 10–15 years. Tau accumulation occurs later, much closer to the onset of neurodegeneration.



10–15%

of people with mild cognitive impairment* go on to develop dementia each year.

*Mild cognitive impairment is an abnormal decline in cognition that, unlike Alzheimer's disease, does not affect daily living. It is considered to be a precursor to the condition.



8–10 YEARS

The average time for which a person with Alzheimer's disease lives after diagnosis.

The Beta amyloid Hypothesis


From genetics – Familiar AD – mutations were identified

APP - amyloid precursor protein
gene on chromosome 21




What do we know about AD?

- 1 - Beta Amyloid is cleaved
- 2-3 - Plaques form outside neurons and disrupt function
- 5 - Misfolded Tau aggregates inside neurons disrupting function
- 6 - Misfolded Tau can spread between neurons




4 -
Neuroinflammation
Structural &
functional changes
in non neuronal
populations
in response to
toxic aggregates

Pro-inflammatory activity in the brain



Neuroinflammation seen through activation of supporting **astrocytes** and resident immune cells - **microglia**



Current medications

Types of drugs approved by the FDA – symptoms relief:


1. Cholinesterase inhibitors – “cholinergic hypothesis”:
increase acetylcholine in the brain to help with memory formation

2. *N*-methyl-d-aspartate receptor antagonists: oppose effects of excitatory neurotransmitter glutamate

- No new AD drugs have been approved by the U.S. FDA since 2003
- Trials are focused on anti-A β and anti-tau agents
- Failures of over 400 trials of these drug classes raise questions as to whether A β and tau proteins are biomarkers or causes

New hypotheses or unfollowed hypotheses

We may finally know what causes Alzheimer's – and how to stop it



P. gingivalis may be the main culprit in Alzheimer's disease
A. DOWSETT, PUBLIC HEALTH ENGLAND/SCIENCE PHOTO LIBRARY

TheScientist


EXPLORING LIFE, INSPIRING INNOVATION

Home / Archive / September 2017 / Features

Do Microbes Trigger Alzheimer's


The once fringe idea is gaining traction among the scientific community.

Sep 1, 2017
JILL U. ADAMS



Home / News & Opinion

Herpes Viruses Implicated in Alzheimer's Disease



A mesh of amyloid- β fibrils entraps *Pseudomonas aeruginosa* bacteria.

The link between chronic gum disease and AD

RESEARCH ARTICLE | HEALTH AND MEDICINE

Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors


Stephen S. Dominy^{1,*†}, Casey Lynch^{1,*}, Florian Ermini¹, Malgorzata Benedyk^{2,3}, Agata Marczyk², Andrei Konradi¹, Mai N...

+ See all authors and affiliations

Science Advances 23 Jan 2019:
Vol. 5, no. 1, eaau3333
DOI: 10.1126/sciadv.aau3333


Higher levels of an enzyme - gingipains, produced by the bacterium *Porphyromonas gingivalis*, have been found in the brains and CSF of AD patients

Gingipains



CTR

AD



Neurons in CA1

RgpB

MAP2

Merge

The link between chronic gum disease and AD

The enzyme was found to cause mice to develop signs of AD

- dying neurons in Hippocampus
- higher levels of β -amyloid protein

The enzyme damaged tau and induced it to aggregate.

A drug anti-gingipain enzyme reduced β -amyloid production and neuronal death, and markers of inflammation.

Spirochetes & AD




6 genera, some causing Lyme disease (*Borrelia burgdorferi*), syphilis (*Troponema pallidum*), and gingivitis (several *Troponema*)

Polymicrobial biofilms formed over decades

Dementia observed in spirochetes-induced diseases; identified in many AD brains

Exposure induces chronic inflammatory response, A β plaques, cortical atrophy



Herpes Virus Type I & AD


In 1,400 post-mortem AD brains, evidence of human herpes viruses 6A (HHV-6A) and 7 (HHV-7) in greater abundance in brain cortical regions

Amyloid- β could prevent HSV1 infection and can bind and aggregate the HSV1 and HHV6 viruses.

Mice that had genetically elevated amyloid- β expression, once infected with HSV1—which can cause encephalitis—were protected against encephalitis, but also had increased amyloid deposits. W.A. Eimer et al. *Neuron*, July 12, 2018.

A recent drug trial targeting the virus (VALZ-PILOT) has been launched [TrialsGov - Valacyclovir 2017]

Pro-inflammatory activity in the brain as a response to pathogens' attack



Amyloid plaques seen as an antimicrobial tool

“The Pathogen hypothesis”

Attention shifted to the microbiome




The brain microbiome contains hundreds of bacterial and fungal species

Comparing the brains of older and younger individuals with and without AD to identify viral residues.

Preliminary evidence shows that the brain microbiome is shifted and is linked to pro-inflammatory activity.

Drs. Tanzi & Moir, Harvard-Mass General


Gut-Brain-Axis and AD dysbiosis



Dysregulation
observed in AD



Can Probiotics Supplementation Alter AD Pathology?



Can Probiotics Treatment Alter AD Pathology in a Transgenic Mouse Model?

Aim 1:

Determine Effects
of Probiotics on
Neurons Death
using NeuN+ Cell
Counts


Aim 2:

Determine effects
of Probiotics on
supporting
astrocytes
using GFAP+ Cell
Counts

Aim 3:

Determine effects
of Probiotics on
microglia
using IBA1+ Cell
Counts

Can Probiotics Treatment Alter AD Pathology in a Transgenic Mouse Model?




Aim 2:
Determine effects of
Probiotics on
supporting
astrocytes
using GFAP+ Cell
Counts

Aim 3:
Determine effects of
Probiotics on
microglia
using IBA1+ Cell
Counts

Can Probiotics Treatment Alter AD Pathology in a Transgenic Mouse Model?

Aim 1:
Determine Effects
of Probiotics on
Neurons Death
using NeuN+ Cell
Counts




Aim 3:
Determine effects of
Probiotics on
microglia
using IBA1+ Cell
Counts

Can Probiotics Treatment Alter AD Pathology in a Transgenic Mouse Model?

Aim 1:
Determine Effects of
Probiotics on
Neurons Death
using NeuN+ Cell
Counts

Aim 2:
Determine effects of
Probiotics on
supporting astrocytes
using GFAP+ Cell
Counts




Possible therapeutics
to combat neuronal
loss

Possible therapeutics
to combat
neuroinflammation

Inexpensive, easy to
administer
therapeutics
to combat costly,
debilitating diseases

Can Probiotics Treatment Alter AD Pathology?



Acknowledgments

Probiotics



Melissa Stanley
MSN '17; DG Scholar

Adam Silver, Ph.D.



Krista McMurry
MSN '18



Destynie Medeiros
Honors BA'19; DG Scholar
Ribicoff recipient

Ketogenic Diet

Marwa Elamin
MSN '17; DG Scholar



Nick Buitrago
MSN



UNIVERSITY OF HARTFORD

THE WOMEN'S ADVANCEMENT INITIATIVE
CONTINUING THE LEGACY OF HARTFORD COLLEGE FOR WOMEN

UNIVERSITY OF HARTFORD

COLLEGE OF ARTS AND SCIENCES